ARDELYX, INC. Cost of Revenue
ARDELYX, INC. (ARDX) reported Cost of Revenue of $5.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- ARDELYX, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $5.76M, a 53.57% decline year-over-year.
- ARDELYX, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $4.81M, a 60.90% decline year-over-year.
- ARDELYX, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $10.85M, a 40.60% decline year-over-year.
- ARDELYX, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $3.98M, a 74.68% decline year-over-year.
- ARDELYX, INC. cost of goods and services sold for fiscal 2025 was $39.54M, a 21.80% decline from fiscal 2024.
- ARDELYX, INC. cost of goods and services sold for fiscal 2024 was $50.56M, a 184.10% increase from fiscal 2023.
- ARDELYX, INC. cost of goods and services sold for fiscal 2023 was $17.80M, a 332.23% increase from fiscal 2022.
- ARDELYX, INC. cost of goods and services sold for fiscal 2022 was $4.12M, a 311.70% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.76M 10-Q · filed 2026-08-06 | $10.57M 10-Q · filed 2026-08-06 | $21.42M derived: sum of 3 quarters · filed 2026-08-06 | $25.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.81M 10-Q · filed 2026-04-30 | $15.66M derived: sum of 2 quarters · filed 2026-04-30 | $19.64M derived: sum of 3 quarters · filed 2026-04-30 | $32.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $14.83M derived: sum of 2 quarters · filed 2026-02-19 | $27.23M derived: sum of 3 quarters · filed 2026-08-06 | $39.54M 10-K · filed 2026-02-19 |
| 2025-09-30 | $3.98M 10-Q · filed 2025-10-30 | $16.39M derived: sum of 2 quarters · filed 2026-08-06 | $28.69M 10-Q · filed 2025-10-30 | $46.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.40M 10-Q · filed 2026-08-06 | $24.71M 10-Q · filed 2026-08-06 | $42.97M derived: sum of 3 quarters · filed 2026-08-06 | $58.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.30M 10-Q · filed 2026-04-30 | $30.57M derived: sum of 2 quarters · filed 2026-04-30 | $46.30M derived: sum of 3 quarters · filed 2026-04-30 | $55.73M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $18.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $33.99M derived: sum of 2 quarters · filed 2026-02-19 | $43.43M derived: sum of 3 quarters · filed 2026-02-19 | $50.56M 10-K · filed 2026-02-19 |
| 2024-09-30 | $15.73M 10-Q · filed 2025-10-30 | $25.16M derived: sum of 2 quarters · filed 2025-10-30 | $32.29M 10-Q · filed 2025-10-30 | $37.37M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $9.44M 10-Q · filed 2025-08-04 | $16.56M 10-Q · filed 2025-08-04 | $21.64M derived: sum of 3 quarters · filed 2026-02-19 | $29.33M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $7.13M 10-Q · filed 2025-05-01 | $12.21M derived: sum of 2 quarters · filed 2026-02-19 | $19.90M derived: sum of 3 quarters · filed 2026-02-19 | $23.39M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $12.77M derived: sum of 2 quarters · filed 2026-02-19 | $16.26M derived: sum of 3 quarters · filed 2026-02-19 | $17.80M 10-K · filed 2026-02-19 |
| 2023-09-30 | $7.69M 10-Q · filed 2024-10-31 | $11.18M derived: sum of 2 quarters · filed 2024-10-31 | $12.72M 10-Q · filed 2024-10-31 | $15.88M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $3.49M 10-Q · filed 2024-08-01 | $5.03M 10-Q · filed 2024-08-01 | $8.19M derived: sum of 3 quarters · filed 2025-02-20 | $8.92M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-02 | $4.70M derived: sum of 2 quarters · filed 2025-02-20 | $5.43M derived: sum of 3 quarters · filed 2025-02-20 | $5.57M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.89M derived: sum of 2 quarters · filed 2025-02-20 | $4.03M derived: sum of 3 quarters · filed 2025-02-20 | $4.12M 10-K · filed 2025-02-20 |
| 2022-09-30 | $732.00K 10-Q · filed 2023-10-31 | $870.00K derived: sum of 2 quarters · filed 2023-10-31 | $955.00K 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $138.00K 10-Q · filed 2023-08-02 | $223.00K 10-Q · filed 2023-08-02 | ||
| 2021-12-31 | $1.00M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |